# Aminothiadiazine derivatives as histamine H2 antagonists.

## Abstract
Compounds of the formula I

## Claims
CLAIMS 1. A compound of the formula I EMI21.1 or a pharmaceutically acceptable salt thereof, whereinR1 and R2 are independently hydrogen, C1 6alkyl, aryl Cl 6 alkyl, heteroaryl Cl alkyl, C3 10cyclo alkyl, hydroxy C2 6 alkyl, or halo C2 6 alkyl, wherein said hydroxy and halo groups are not substituted on the carbon atom adjacent to the nitrogen atom or R1 and R2 together represent CH2 q wherein q is 4 to 7, to form together with the nitrogen atom to which they are attached a 5 8 membered saturated ring n is an integer from 1 to 6 Z is 1,3 phenylene, 1,4 phenylene, 2,4 pyridyl wherein the R1R2N CH2 n group is in the 4 position m is zero or oneY is oxygen, sulphur or methylene p is two, three or four and R3 and R4 are independently hydrogen, C1 6alkyl, aryl, aryl C16 alkyl or pyridy1 C16 alkyl, or R3 and R4 together with the carbon atoms to which they are attached form a benzene ring optionally substituted by Cl 6alkyl. 2. A compound according to claim 1 wherein R3 and R are independently hydrogen, Cl 6alkyl, aryl, aryl C16 alkyl or pyridyl C1 6 alkyl. 3. A compound according to claim 2 wherein R3 and 4R are both hydrogen. 4. A compound according to any one of claims 1 to 3 wherein Z is 2,4 pyridyl. 5. A compound according to any one of claims 1 to 3 wherein Z is 1,3 phenylene. 6. A compound according to any one of claims 1 to 5 wherein R1R2N CH2 n is piperidinomethyl. 7. A compound according to any one of claims 1 to 6 wherein m is zero and Y is oxygen. 8. A compound according to claim 1 which is 3 3 3 piperidinomethyl phenoxy propylamino 5,6 dihydro l,2,4 thiadiazine 1,l dioxide or a pharmaceutically acceptable salt thereof 3 3 3 piperidinomethyl phenoxy propylamino 1,2,4 benzo thiadiazine l,l dioxide or a pharmaceutically acceptable salt thereof 3 3 4 dimethylaminomethyl pyrid 2 yloxy propylamino 1,2,4 benzothiadiazine l,l dioxide or a pharmaceutically acceptable salt thereof 3 E3 4 piperidinomethyl pyrid 2 yloxy propylamino 1,2,4 benzothiadiazine l,l dioxide or a pharmaceutically acceptable salt thereof 3 3 4 piperidinomethyl pyrid 2 yloxy propylamino 5,6 dihydro l,2,4 thiadiazine l,l dioxide or a pharmaceutically acceptable salt thereof 3 2 4 dimethylaminomethyl pyrid 2 ylmethylthio ethyl amino 1,2,4 benzothiadiazine l,1 dioxide or a pharmaceutically acceptable salt thereof or 3 2 4 dimethylaminomethyl pyrid 2 ylmethylthio ethyl amino 5,6 dihydro l,2,4 thiadiazine l,l dioxide or a pharmaceutically acceptable salt thereof. 9. Crystalline 3 3 3 piperidinomethyl phenoxy propylamino 1,2,4 benzothiadiazine 1,1 dioxide. 10. A compound according to any one of claims 1 to 9 for use as a therapeutic agent. 11. A compound according to any one of claims 1 to 9 for use as an H2 antagonist. 12. A pharmaceutical composition which comprises a compound according to any of claims 1 to 9 and a pharmaceutically acceptable carrier. 13. A process for preparing a compound of the formula I as defined in claim 1 or a pharmaceutically acceptable salt thereof which comprises a reacting a compound of the formula II with a compound of the formula III R1R2N CH2 n Z CH2 m Y CH2 p 2 NH2 II EMI24.1 wherein R1 R2 R3 R4, Z, V, m, n and p are as defined in claim 1, and Q is a group displaceable by amine or b reducing a compound of the formula IV or V EMI24.2 wherein R1 R2 R3 R4, Z, V, n, m and p are as hereinbefore defined, R5 is a precursor of a groupR1R2N CH2 n as hereinbefore defined and R6 is a group CONH or CH N or c for preparing compounds wherein Z is phenylene, m is zero and Y is oxygen, reacting a compound of the formula VI or chemical equivalent thereof with a compound of the formula VII EMI25.1 R1 2 3 4 wherein R , R , R , R , n and p are as hereinbefore defined, and Q1 is a moiety displaceable by phenol or chemical equivalent thereof or d for preparing compounds wherein m is one and Y is sulphur, reacting a compound of the formula VIII or chemical equivalent thereof with a compound of the formula IX 12 R R N CH2 n Z CH2SH VIII EMI25.2 wherein R1, R2, R3, R4, Z, n and p are as hereinbefore defined, and Q2 is a moiety displaceable by thiol or chemical equivalent thereof or e for preparing compounds wherein m is one and Y is sulphur, reacting a compound of the formula X with a compound of the formula XI or chemical equivalent thereof R1R2N CH2 Z CH Q3 X EMI26.1 wherein R1, R2, R3, R4, n, Z and p are as hereinbefore defined, and Q3 is a moiety displaceable by thiol or chemical equivalent thereof or f for preparing compounds wherein R3 and R4 together with the carbon atoms to which they are attached form a benzene ring optionally substituted by C1 6alkyl, cyclizing a compound of the formula XII EMI26.2 wherein R1, R2, n, Z, m, Y and p are as hereinbefore defined, R is hydrogen or C1 6alkyl, and Q4 is a moiety displaceable by amine and optionally thereafter forming a pharmaceutically acceptable salt. Claims for Austria 1. A process for preparing a compound of the formula I EMI27.1 or a pharmaceutically acceptable salt thereof, wherein and R are independently hydrogen, C1 6alkyl, aryl C1 6 alkyl, heteroaryl C1 6 alkyl, C3 10cyclo alkyl, hydroxy C26 a1kyl, or halo C26 a1kyl, wherein said hydroxy and halo groups are not substituted on the carbon atom adjacent to the nitrogen atom orR1 and R2 together represent CH2 q wherein q is 4 to 7, to form together with the nitrogen atom to which they are attached a 5 8 membered saturated ring n is an integer from 1 to 6 Z is 1,3 phenylene, 1,4 phenylene, 2,4 pyridyl wherein the R1R2N CH2 n group is in the 4 position m is zero or oneY is oxygen, sulphur or methylene p is two, three or four andR3 and R4 are independently hydrogen, C1 6alkyl, aryl, aryl C16 alkyl or pyridyl C16 a1kyl, or R ana R together with the carbon atoms to which they are attached form a benzene ring optionally substituted by Cl 6alkyl which process comprises a reacting a compound of the formula II with a compound of the formula III R1R2N CH2 n Z CH2 m Y CH2 p NH2 Il EMI28.1 wherein R1, R2, R3, R4, Z, V, m, n and p are as defined in claim 1, and Q is a group displaceable by amine or b reducing a compound of the formula IV or V EMI28.2 wherein R1 R2 R3 R4 Z, Y, d m and p are as hereinbefore defined, R5 is a precursor of a group R12 6. R N CH2 n as hereinbefore defined and R is a group CONH or CH N or c for preparing compounds wherein Z is phenylene, m is zero and Y is oxygen, reacting a compound of the formula VI or chemical equivalent thereof with a compound of the formula VII EMI29.1 wherein R1, R2, R3, R4, n and p are as hereinbefore defined, and Q1 is a moiety displaceable by phenol or chemical equivalent thereof or d for preparing compounds wherein m is one and Y is sulphur, reacting a compound of the formula VIII or chemical equivalent thereof with a compound of the formula IX R1R2N CH2 Z CH2SH VIII EMI29.2 wherein R1 R2 R3 R4, Z, n and p are as hereinbefore defined, and Q2 is a moiety displaceable by thiol or chemical equivalent thereof or e for preparing compounds wherein m is one and Y is sulphur, reacting a compound of the formula X with a compound of the formula XI or chemical equivalent thereof R1R2N CH2 Z CH2 Q3 X EMI30.1 wherein R1, R2, R3, R4, n, Z andp are as hereinbefore defined, and Q3 is a moiety displaceable by thiol or chemical equivalent thereof or f for preparing compounds wherein R3 and R4 together with the carbon atoms to which they are attached form a benzene ring optionally substituted by Cl 6alkyl, cyclizing a compound of the formula XII EMI30.2 wherein R1, R2, n, Z, m, Y and p are as hereinbefore defined, R is hydrogen or C1 6alkyl, and Q4 is a moiety displaceable by amine and optionally thereafter forming a pharmaceutically acceptable salt. 2. A process according to claim 1 for preparing a compound wherein R3 and R4 are independently hydrogen, Cl 6alkyl, aryl, aryl C16 alkyl or pyridyl C16 alkyl. 3. A process according to claim 2 for preparing a compound wherein R3 and R4 are both hydrogen. 4. A process according to any one of claims 1 to 3 for preparing a compound wherein Z is 2,4 pyridyl. 5. A process according to any one of claims 1 to 3 for preparing a compound wherein Z is 1,3 phenylene. 6. A process according to any one of claims 1 to 5 12 for preparing a compound wherein R R N CH2 n is piperidinomethyl. 7. A process according to any one of claims 1 to 6 for preparing a compound wherein m is zero and Y is oxygen. 8. A process according to claim 1 for preparing 3 3 3 piperidinomethyl phenoxy propylamino 5,6 dihydro l,2,4 thiadiazine l,l dioxide or a pharmaceutically acceptable salt thereof 3 3 3 piperidinomethyl phenoxy propylamino 1,2,4 benzo thiadiazine l,l dioxide or a pharmaceutically acceptable salt thereof 3 3 4 dimethylaminomethyl pyrid 2 yloxy propylamino l,2,4 benzothiadiazine l,1 dioxide or a pharmaceutically acceptable salt thereof 3 3 4 piperidinomethyl pyrid 2 yloxy propylaminol 1,2,4 benzothiadiazine l,l dioxide or a pharmaceutically acceptable salt thereof 3 3 4 piperidinomethyl pyrid 2 yloxy propylamino 5,6 dihydro l,2,4 thiadiazine 1,1 dioxide or a pharmaceutically acceptable salt thereof 3 2 4 dimethylaminomethyl pyrid 2 ylmethylthio ethyl amino 1,2,4 benzothiadiazine l,l dioxide or a pharmaceutically acceptable salt thereof or 3 2 4 dimethylaminomethyl pyrid 2 ylmethylthio ethyl amino 5,6 dihydro 1,2,4 thiadiazine l,1 dioxide or a pharmaceutically acceptable salt thereof. 9. A process for preparing a pharmaceutical composition which comprises bringing into association a compound as defined in claim 1 and a pharmaceutically acceptable carrier.

## Description
CHEMICAL COMPOUNDS This invention relates to thiadiazine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use as histamineH2 antagonists. Histamine, a physiologically active compound endogenous in mammals, exerts its action by interacting with certain sites called receptors. One type of receptor is known as a histamine Hl receptor Ash andSchild, Brit. J. Pharmac. Chemother. 27 427 1966 and the actions of histamine mediated through these receptors are blocked by drugs commonly called antihistamines histamine H1 antagonists a common example of which is mepyramine. A second type of histamine receptor is known as the H2 receptor Black et al. Nature 1972, 236, 385 . These receptors are not blocked by mepyramine but are blocked by burimamide. Compounds which block these histamine 2 receptors are called histamine H2antagonists. Histamine H2 antagonists are useful in treating disease conditions caused by the biological effects of histamine mediated through H2 receptors, for example, as inhibitors of gastric acid secretion, in the treatment of inflammation mediated through histamine H2 receptors and as agents which act on the cardiovascular system, for example, as inhibitors of effects of histamine on blood pressure mediated through histamine H2 receptors. Cimetidine is an example of a histamine H2antagonist. Cimetidine has been shown to be useful in the treatment of duodenal, gastric, recurrent and stomal ulceratXon, and reflux oesophagitis and in the management of patients who are at high risk from haemorrhage of the upper gastrointestinal tract. In some physiological conditions the biological actions of histamine are mediated through both histamineH1 and H2 receptors and blockade of both types of receptors is useful. These conditions include inflammation mediated by histamine, for example skin inflammation, and those hypersensitivity responses due to the action of histamine at H1 and H2 receptors, for example allergies. Accordingly the present invention provides compounds of the formula I EMI2.1 and pharmaceutically acceptable salts thereof, whereinR1 and R2 are independently hydrogen, C1 6alkyl, aryl C1 6 alkyl, heteroaryl C1 6 alkyl, C3 10cycloaikyl, hydroxy C2 6 alkyl, or halo C2 6 alkyl, wherein said hydroxy and halo groups are not substituted on the carbon atom adjacent to the nitrogen atom or R1 and R2 together represent CH2 q wherein q is 4 to 7, to form together with the nitrogen atom to which they are attached a 5 8 membered saturated ring n is an integer from 1 to 6 Z is 1,3 phenylene, 1,4 phenylene, 2,4 pyridyl wherein the R1R2N CH2 n group is in the 4 position m is zero or one Y is oxygen, sulphur or methylene p is two, three or four andR3 and R4 are independently hydrogen, C1 6alkyl, aryl, aryl C1 6 alkyl or pyridyl C1 6 alkyl, or R3 andR together with the carbon atoms to which they are attached form a benzene ring optionally substituted by C16alkyl. When used herein alkyl means groups that are either straight chained or branched. In general preferred alkyl groups are methyl and ethyl. Suitably in the definitions of R1, R2, R3 and R4 aryl is phenyl, aryl C16 alkyl is phenyl C1 6 alkyl and heteroaryl C1 6 alkyl is furanyl C1 6 alkyl or thienyl C1 alkyl. Suitably R1 is aryl C16 alkyl for example benzyl or phenethyl, heteroaryl C1 6 alkyl for example furanyl C16 alkyl such as furanylmethyl or thienyl C1 6 alkyl such as thienylmethyl, halo C2 6 alkyl for example 2,2,2 trifluoroethyl, or C cycloalkyl for example 3 19 cyclohexyl. More suitably R is C1 6alkyl, for example methyl, ethyl or propyl. Suitably R2 is hydrogen or Cl 6alkyl, for example methyl, ethyl or propyl. Suitably R1 and R2 have the same value, for example they both are methyl or they are both ethyl.In another suitable aspect R1 and R2 together with the nitrogen atom to which they are attached form a pyrrolidino or piperidino ring. Preferably n is one. Suitably Z is 1,3 phenylene. Suitably Z is 2,4pyridyl. Favourably when Z is 1,3 phenylene, m is zero and preferably Y is oxygen. Favourably when Z is 2,4pyridyl m is one and preferably Y is sulphur. In an alternative favourable aspect when Z is 2,4 pyridyl, m is zero and preferably Y is oxygen. Suitably m and p when added together equals three, that is suitably p is two when m is one, and suitably p is three when m is zero. Examples of favoured groupsR1R2N CH2 n Z CH2 m Y CH2 p p CH2 p 4 dimethylaminomethylpyr id 2 ylmethylthioethyl, 4 piperidinomethylpyr id 2 ylmethylthioethyl, 4 dimethylaminomethylpyr id 2 yloxypropyl, 4 piperidinomethylpyrid 2 yloxypropyl, 3 dimethylaminomethylphenoxypropyl, 3 piperidinomethylphenoxypropyl, 3 dimethylaminomethylphenylmethylthioethyl or 3 piperidinomethylphenylmethylthioethyl. In one aspect of this invention R3 and R4 are independently hydrogen, C1 6alkyl, aryl, aryl Cl 6 alkyl or pyridyl C1 6 alkyl. Suitably R3 is hydrogen, C1 6alkyl for example methyl, ethyl, propyl or butyl, aryl C1 6 alkyl for example benzyl, phenethyl, or is pyridylmethyl. Suitably R4 is hydrogen or C1 6alkyl for example methyl or ethyl. In a preferred aspect R3 and R4 are both hydrogen. In a further aspect R3 and R4 together with the carbon atoms to which they are attached form a benzene ring. The compounds of the formula I are depicted in the 4 H tautomeric form, and exist in equilibrium with the 2 H tautomeric form and the tautomeric form with an exocyclic double bondEMI5.1 The present application covers all isomeric and tautomeric forms, and mixtures thereof, of the compounds of the formula I . Specific compounds of this invention include 3 3 3 piperidinomethyl phenoxy propylamino 5,6 dihydro 1,2,4 thiadiazine l,l dioxide and pharmaceutically acceptable salts thereof 3 3 3 piperidinomethyl phenoxy propylamino l,2,4 benzo thiadiazine l,l dioxide and pharmaceutically acceptable salts thereof 3 3 4 dimethylaminomethyl3pyrid 2 yloxy propylamino 1,2,4 benzothiadiazine l,l dioxide and pharmaceutically acceptable salts thereof 3 E3 4 piperidinomethyl3pyrid 2 yloxy propylamino 1,2,4 benzothiadiazine l,l dioxide and pharmaceutically acceptable salts thereof 3 3 4 piperidinomethyl pyrid 2 yloxy propylam√≠no 5,6 dihydro 1,2,4 thiadiazine 1,l dioxide and pharmaceutically acceptable salts thereof 3 2 4 dimethylaminomethyl pyrid 2 ylmethylthio ethyl amino 1,2,4 benzothiadiazine 1,1 dioxide and pharmaceutically acceptable salts thereof and 3 2 4 dimethylaminomethyl pyrid 2 ylmethylthio ethyl amino 5,6 dihydro l,2,4 thiadiazine l,l dioxide and pharmaceutically acceptable salts thereof. The activity of the compounds of formula I as histamine H2 antagonists can be demonstrated by their ability to inhibit histamine stimulated secretion of gastric acid from the lumen perfused stomachs of rats anaesthetised with urethane, and to reverse histamineinduced inhibition of contractions of the isolated rat uterus. These are actions of histamine which, according to Ash and Schild, Bait. J. Pharmac. Chemother. 27 247 1966 , are not mediated by histamine H1 receptors. The histamine H2 antagonist activity of the compounds can also be demonstrated by the inhibition of histaminestimulated acid secretion in the Heidenhain Pouch Dog, the inhibition of histamine induced tachycardia in the isolated guinea pig right atrium and the inhibition of histamineinduced vasodilatation in the anaesthetised cat. The measurement of inhibition of histamine stimulated secretion of gastric acid from the lumen perfused stomachs of rats anaesthetised with urethane, and the measurement of inhibition of histamine induced tachycardia in the isolated guinea pig right atrium, are detailed inEuropean Patent Application Publication No 49173. To illustrate the level of activity of the compounds of the invention we have determined that where tested the products of the Examples have ED50 values in the lumenperfused rat test of less than one micromol kg 1 i.v. and pA2 values in the guinea pig atrium test of more than six. In order to use compounds of formula I or pharmaceutically acceptable salts thereof for medical purposes, they are normally formulated in accordance with standard pharmaceutical practice as pharmaceutical compositions. The invention further provides pharmaceutical compositions comprising a compound of formula I above or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier. Compounds of formula I and their pharmaceutically acceptable salts may be administered orally, parenterally, cutaneously or rectally. Compounds of formula I and their pharmaceutically acceptable salts which are active when given orally can be formulated as syrups, tablets, capsules and lozenges.A syrup formulation will generally consist of a suspension or solution of the compound or salt in a suitable liquid carrier for example, ethanol, glycerine or water with a flavouring or colouring agent. Where the composition is in the form of a tablet, any suitable pharmaceutical carrier routinely used for preparing solid formulations may be used. Examples of such carriers include magnesium stearate, starch, lactose, sucrose and cellulose. Typical parenteral compositions consist of a solution or suspension of the compound or pharmaceutically acceptable salt thereof in a sterile aqueous carrier or parenterally acceptable oil. Typical compositions for administration to the skin include lotions and creams in which the compound of formula I or pharmaceutically acceptable salt thereof is contained in a liquid vehicle. A typical suppository formulation comprises a compound of formula I or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and or lubricating agent such as gelatin or cocoa butter or other low melting vegetable waxes or fats. Preferably the composition is in unit dose form such as a tablet or capsule so that the patient may administer to himself a single dose. Each dosage unit for oral administration contains preferably from 15 to 250 mg and for parenteral administration contains preferably 0.5 to 25 mg of a compound of the formula I or a pharmaceutically acceptable salt thereof calculated as the free base. The invention also provides a method of blocking histamine H2 receptors which comprises administering to an animal an effective amount to block said receptors of a compound of the formula I or pharmaceutically acceptable salt thereof. The pharmaceutical compositions of this invention will normally be administered to a subject for the treatment of peptic ulcers and other conditions caused or exacerbated by gastric acidity in the same general manner as that employed for known histamine H2 antagonists, due allowance being made in terms of dose levels for the potency of the compound of the present invention relative to known histamine H2 antagonists. Thus an adult patient will receive an oral dose of between 15 mg and 1500 mg and preferably between 20 mg and 250 mg or an intravenous, subcutaneous, or intramuscular dose of between 0.5 mg and 150 mg, and preferably between 1.0 mg and 20 mg of compound of formula I or pharmaceutically acceptable salt thereof calculated as the free base, the composition being administered 1 to 6 times per day. In a further aspect of this invention the compounds of the formula I and pharmaceutically acceptable salts thereof may be prepared by a process which comprises a reacting a compound of the formula II with a compound of the formula III R1R2N CH2 n Z CH2 m Y CH2 p NH2 II EMI9.1 wherein R1 R2 R3 R4 Z, V, m n and p are as hereinbefore defined, and Q is a group displaceable by amine or b reducing a compound of the formula IV or V EMI9.2 wherein R1, R2, R3, R4, Z, V, n, m and p are as hereinbefore defined, R5 is a precursor of a group R1R2N CH2 n as hereinbefore defined and R6is a group CONH or CH N or c for preparing compounds wherein Z is phenylene, m is zero and Y is oxygen, reacting a compound of the formula VI or chemical equivalent thereof with a compound of the formula VII EMI10.1 wherein R1, R2, R3, R4, n and p are as hereinbefore 1. defined, and Q1 is a moiety displaceable by phenol or chemical equivalent thereof or d for preparing compounds wherein m is one and Y is sulphur, reacting a compound of the formula VIII or chemical equivalent thereof with a compound of the formula IX RlR2N CH2 n Z CH2SH VIII EMI10.2 wherein R1, R2, R3, R4, Z, n and p are as hereinbefore defined, and Q2 is a moiety displaceable by thiol or chemical equivalent thereof or e for preparing compounds wherein m is one and Y is sulphur, reacting a compound of the formula X with a compound of the formula XI or chemical equivalent thereof R1R2N CH2 n Z CH2 Q3 Q X EMI11.1 wherein R1, R2, R3, R4, n, Z and p are as hereinbefore defined, and Q3 is a moiety displaceable by thiol or chemical equivalent thereof or f for preparing compounds wherein R3 and R4 together with the carbon atoms to which they are attached form a benzene ring optionally substituted by Cl 6alkyl, cyclizing a compound of the formula XII EMI11.2 wherein R1, R2, n, Z, m, Y and p are as hereinbefore defined, R is hydrogen or Cl 6alkyl, and Q4 is a moiety displaceable by amine and optionally thereafter forming a pharmaceutically acceptable salt. Suitably Q is C1 6alkylthio, benzylthio, chloro or bromo. Favourably Q is methylthio. The reaction between a compound of the formula II and a compound of the formula III can be performed in the absence of solvent at an elevated temperature, or in the presence of a substantially inert solvent such as a polar solvent, for example pyridine, anisole or a C1 6 alkanol, at for example a temperature between ambient and reflux. When Q is methylthio the reaction for example may be performed at 120 1700C in the absence of solvent. In the compounds of the formula IV in one suitable aspect R5 is a group R1R2N CH2 x CO CH2 y wherein x y n l. Favourably x and y are both zero so that the group R1R2NCO is a precursor to the group R1R2NCH2 . The reduction of such a group RlR2N CH2 x CO CH2 y may be performed with a hydride for example lithium aluminium hyaride. In an alternative aspect R5 is a group CHO CH2 n 1 , which may be converted to a group R1R2N CH2 on reaction 12 n with an amine R R NH under conditions of reductive amination. Furthermore in another suitable aspect R5 may be a group HO CH2 n which may be converted directly to R1R2N CH2 , or indirectly thereto for example via a moiety such as Br CH2 n and thence to R1R2N CH2 n . Such transformations may be carried out in conventional manner. The compounds of the formula V may be reduced to form compounds of the formula I , for example using lithium aluminium hydride in an ether solvent when R6 is CONH and for example using a boronydride in an alkanol, lithium aluminium hydride in an ether solvent, or catalytically hydrogenating when R is CH N . In the reaction between the compounds of the formulae VI and VII suitably Q1 is chloro or bromo. Suitably the reaction is performed under basic conditions, for example the anion of the compound of the formula VI may be generated, for example using sodium hydride. The reaction is performed in a suitable aprotic solvent for example dimethylformamide at a non extreme temperature for example between OOC and 1000C, suitably between ambient and 700C. Suitably in the reaction between the compounds of the formulae VIII and IX 42 is chloro, bromo, arylsulphonyloxy for example 4 methylbenzenesulphonyloxy or C .alkanesulphonyloxy for example methanesulphonyl oxy. Such reactions are generally performed in the presence of a base for example triethylamine, an alkoxide or a hydroxide. Suitably in the reaction between the compounds of the formula X and XI Q3 is chloro, bromo, hydroxy, C1 6alkoxy for example methoxy, C1 6alkanoyloxy for example acetoxy, arylsulphonyloxy for example 4 methyl benzenesulphonyloxy, or C 1 6 alkanesulphonyloxy for example methanesulphonyloxy. Preferably Q3 is hydroxy in which case the reaction between the compounds of the formulae X and XI is performed under acidic conditions. When Q3 is chloro or bromo it is preferable to perform the reaction in the presence of a strong base for example sodium ethoxide in ethanol. When Q3 is an arylsulphonyloxy or alkylsulphonyloxy group the reaction is preferably performed under mildly basic conditions for example in pyridine solution. The cyclisation of a compound of the formula XII is suitably performed in an organic solvent. Suitably 4.Q is a Cl 4alkylthio group for example methylthio. Pharmaceutically acceptable acid addition salts of the compounds of the formula I may be prepared from the corresponding base of the compounds of the formula I in conventional manner. For example the base may be reacted with an acid in a Cl qalkanol, or an ion exchange resin may be used. The salts of the compounds of the formula I may be interconverted using ion exchange resins.Non pharmaceutically acceptable salts are therefore of use as they can be converted to pharmaceutically acceptable salts. Suitable pharmaceutically acceptable acid addition salts of the compounds of the formula I include those formed with hydrochloride, hydrobromic, sulphuric, phosphoric, acetic, citric, maleic, lactic, ascorbic, fumaric, oxalic, methanesulphonic and ethanesulphonic acids. The compounds of the formula II , VIII and X are preparable by the methods of European PatentApplication Publication Nos 13071, 49173 and 89153 or in the case of compounds of the formulae VIII by a modification thereof. The compounds of the formula III are known from UK Patent No 1419994. The compounds of the formula IV may be prepared in a manner analogous to that described for the preparation of compounds of the formula I , for example reacting a compound of the formula III with an analogue of a compound of the formula II wherein R1R2N CH2 n is replaced by R5 provided that R5 is suitably protected as necessary. The compounds of the formula V wherein R6 is CH N may be prepared by the reaction of a compound of the formula XIII with a compound of the formula XIV R1R2N CH2 n Z CH2 mY CH2 p 1CHO XIII EMI15.1 wherein R1, R2, R3, R4, n, m, Z, Y and p are as hereinbefore defined, optionally in the presence of an acid catalyst. The compounds of the formula V wherein R6 is CONHmay be prepared by the reaction of a compound of the formula XIV with an activated derivative of a compound of the formula XV R1R2N CH2 n Z CH2 mY CH2 p 1CO2H XV wherein R1, R2 R3, R4, n, m, Z, Y and p are as hereinbefore defined. Suitable active derivatives are acyl halides, anhydrides and activated esters. The aldehydes of the formula XIII may be prepared for example by reacting a compound of the formula XVI R1R2N CH2 n Z OH XVI wherein R1, R2, n, and Z are as hereinbefore defined, with a protected hydroxypropionaldehyde for example protected as a cyclic acetal and deprotecting.The acid of the formula XV and derivatives thereof may be prepared in similar manner for example by reacting a compound of the formula XVI with a protected hydroxy prop ironic acid and if necessary deprotecting and or converting to the desired activated acid derivative. The compounds of the formula VI are preparable for example by the methods of Turner et al J. Org. Chem. 24 p 1952 1959 . The compounds of the formulae VII , IX and XI may be prepared for example by methods analogous to that described for the reaction of compounds of the formulae Il and III , that is reacting a compound of the formula III with 2CH, Ql CH2 pNH2, or HS2 CH2 pNH2 wherein the nature of the groups Q and Q is such that the desired reaction occurs. The compounds of the formula XII for example may be prepared by the methods ofBE 892350. The following Examples serve to illustrate this invention. Example 1 3 3 3 Piperidinomethyl phenoxy propylamino 5,6 dihydro 1,2, 4 thiadiazine 1, 1 dioxide 3 3 Piperidinomethyl phenoxy propylamine 2.91 g and 3 methylthio 5,6 dihydro 1,2,4 thiadiazine 1,l dioxide 1.90 g were combined and heated at 150 50C for 4 hours.The melt was allowed to cool and washed with hot water.The mixture was allowed to cool and the water decanted.The residue was washed with water and washed with ether to afford the title product. This was treated with dilute ethanolic HC1 to form a solid which was recrystallised from methanol water to afford crystalline 3 3 3 piperidinomethyl phenoxy propylamino 5,6 dihydro l,2,4 thiadiazine l,l dioxide monohydrochloride 2.94 g , m.p.229 2320C. Example 2 3 3 3 Piperidinomethyl phenoxy propylamino 1,2,4 benzothiadiazine l,l dioxide 3 3 Piperidinomethyl phenoxy propylamine 1.24 g and 3 methylthio l,2,4 benzothiadiazine l,l dioxide 1.14 g were fused at 140 1500C for 2 hours. The mixture was cooled, dissolved in isopropanol, and evaporated under reduced pressure to afford a residue. This residue was left standing with diethyl ether for 16 hours at OOC, to give a white solid which was recrystallised from isopropanol to afford the title product in crystalline form, m.p. 147 148 C. Example 3 3 2 4 Dimethylaminomethylpyrid 2 ylmethylthio ethylamino 5, 6 dihydro 1, 2, 4 thiadiazine 1, 1 dioxide 2 4 Dimethylaminomethylpyrid 2 ylmethylthio ethylamine 0.9 g and 3 methylthio 5,6 dihydro 1,2,4 thiadiazine 1,1 dioxide 0.9 g were fused at 130 1400C for 2 hours. The mixture was cooled, washed with diethyl ether and subjected to chromatography on silica gel h.p.l.c., 250 mm x 15 mm column eluting with 100 CH2C12 grading to 95 CH2C12 5 CH30H . The desired fractions were collected and evaporated under reduced pressure to afford the title compound as an oil 0.7 g .This was treated with oxalic acid in ethanol to give a solid which was recrystallised from methanol to afford crystalline 3 2 4 dimethylaminomethylpyrid 2 ylmethylthio ethylamino 5,6 dihydro 1,2,4 thiadiazine l,l dioxid dioxalate 0.67 gi, m.p. 177 80C. Example 4 3 2 4 Dimethylaminomethvlpyrid 2 ylmethylthio ethylamino 1,2,4 benzothiadiazine l,l dioxide 2 4 Dimethylaminomethylpyrid 2 ylmethylthio ethyl amine 1.0 g and 3 methylthio l,2,4 benzothiadiazine 1,l dioxide 1.0 g were fused at 140QC for 2 hours. The reaction mixture was cooled to afford the title compound as a crude residue, which was dissolved in ethanol and treated with oxalic acid 2.0 g to afford crystals.These were recrystallised from methanol to afford 3 2 4 dimethylaminomethylpyrid 2 ylmethylthio ethylamino l,2,4 benzothiadiazine 1,l dioxide dioxalate 1.2 g , m.p. l57 80C. Example 5 3 3 4 Dimethylaminomethylpyrid 2 yloxy PropYlaminol 1, 2, 4 benzothiadiazine l,1 dioxide 3 4 Dimethylaminomethylpyrid 2 yloxy propylamine 1.1 g and 3 methylthio 1,2,4 benzothiadiazine 1,1 dioxide 1.0 g were fused at 140 1500C for 2 hours.The reaction mixture was cooled to afford the title compound as a crude residue, which was dissolved in ethanol 5 ml and treated with oxalic acid 1.0 g in ethanol 5 ml to afford a solid. This solid was recrystallised from methanol to afford crystalline 3 3 4 dimethylaminomethylpyrid 2 yloxy propylamino 1,2,4 benzothiadiazine l,l dioxide dioxalate, m.p. 181 20C. Example 6 3 3 4 Piperidinomethylpyrid 2 yloxy ProPylamino 5,6 dihydro l, 2, 4 thiadiazine l,l dioxide 3 4 Piperidinomethylpyrid 2 yloxy propylamine 1.2 g and 3 methylthio 5,6 dihydro 1,2,4 thiadiazine l,l dioxide 0.9 g were heated at 1400C for 2 hours.The reaction mixture was cooled to afford the title compound as a pale orange oil. This was treated with oxalic acid in ethanol to afford solid which was recrystallised from ethanol to give crystalline 3 3 4piperidinomethylpyrid 2 yloxy propylamino 5,6 dihydro l,2,4 thiadiazine 1,1 dioxide dioxalate 0.51 g , m.p. 155 60C. Example 7 3 3 4 Piperidinomethvlpyrid 2 yloxy propylamino 1,2,4 benzothiadiazine l,l dioxide 3 4 Piperidinomethylpyrid 2 yloxy propylamine 1.2 g and 3 methylthio 1,2,4 benzothiadiazine 1,1 dioxide 1.1 g were heated at 1450C for 2 hours. The reaction mixture was cooled to afford the title compound as a crude residue. This residue was dissolved in ethanol and treated with oxalic acid 2 g to afford a solid. This solid was recrystallised from methanol to give 3 3 4 piperidinomethylpyrid 2 yloxy propylamino 1,2,4 benzothiadiazine l,l dioxide dioxalate 1.32 g , m.p. 186 70C. Example 8 A pharmaceutical composition for oral administration is prepared containing by weightEMI20.1 tb SEP t3 3 4 piperidinomethylpyrid 2 yloxy SEP 55 tb SEP propylamino SEP l,2,4 benzothiadiazine l,1 SEP tb SEP A SEP dioxide SEP dioxalate tb SEP Dibasic SEP calcium SEP phosphate SEP dihydrate SEP 20 tb SEP Approved SEP colouring SEP agent SEP 0.5 tb SEP Polyvinylpyrrolidone SEP 4.0 tb SEP Microcrystalline SEP Cellulose SEP 8.0 tb SEP Maize SEP Starch SEP 8.0 tb B SEP Sodium SEP glycollate SEP 4.0 tb SEP Magnesium SEP Stearate SEP 0.5 tb by mixing together the ingredients A substituting lactose or microcrystalline cellulose for dibasic calcium phosphate dihydrate if desired , adding a concentrated solution of polyvinylpyrrolidone and granulating, drying and screening the dried granules adding the ingredients B to the dried granules and compressing the mixture into tablets containing 100 mg, 150 mg or 200 mg of the free base. Other compounds of the invention, for example those specifically described in Examples 1 to 6 can be formulated into pharmaceutical compositions by a similar procedure. The compounds of this invention, where tested, show no overt signs of toxicity at doses which are a pertinent multiple of the therapeutic dose.